|Bid||110.27 x 3000|
|Ask||110.30 x 800|
|Day's Range||109.93 - 111.42|
|52 Week Range||73.69 - 116.61|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.25 (2.04%)|
|1y Target Est||N/A|
INDIANAPOLIS, Oct. 16, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (LLY) has elected Karen Walker as a new member, effective December 1, 2018. As a member of Lilly's board, she will serve on both the Audit Committee and the Public Policy and Compliance Committee. Walker is the Senior Vice President and Chief Marketing Officer at Cisco where she has worked since 2009.
INDIANAPOLIS , Oct. 15, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2018 of $0.5625 per share on outstanding common ...
- Forty-one abstracts supporting Taltz® and Olumiant® reveal new data including findings in ankylosing spondylitis (radiographic axial spondyloarthritis), psoriatic arthritis, systemic lupus erythematosus ...
- National survey uncovers majority of people living with MBC say the daily stress and anxiety they experience associated with the disease can impact everything from relationships to careers, with many ...
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 10, 2018 /PRNewswire/ -- Novel results based on data from the landmark EMPA-REG OUTCOME® trial were published in the journal Circulation which suggest that treatment with Jardiance® positively impacts life expectancy in adults with type 2 diabetes and established cardiovascular disease, Boehringer Ingelheim and Eli Lilly and Company (LLY) announced today. Using actuarial methods*, and assuming that the demonstrated beneficial effects of Jardiance remain consistent with long-term use, Jardiance was estimated to extend life expectancy by 1 to 4.5 years on average, depending on age, when compared with placebo. This analysis suggests that treatment with Jardiance could add years of life.
Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
Data from abemaciclib, pemetrexed and ramucirumab late-stage clinical development programs in multiple difficult-to-treat tumor types New data for pegilodecakin used as a single agent and in combination ...
The Dow Jones Industrial Average fell 0.75 percent to close at 26,627.48, while the S&P 500 Index dropped 0.82 percent to close at 2,901.61. The Nasdaq Composite Index shed 1.81 percent to close at 7,879.51.
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 4, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Tradjenta® on cardiovascular safety and kidney outcomes in adults with type 2 diabetes at high risk for heart and/or kidney disease. The study met its primary endpoint, with Tradjenta demonstrating a similar cardiovascular safety profile compared with placebo when added to standard of care.
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 4, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) announced today that empagliflozin met the primary efficacy endpoint, defined as a change from baseline in A1C versus placebo after 26 weeks of treatment, for all doses investigated (2.5, 10 and 25 mg) in the Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III program in adults with type 1 diabetes. The EASE program results were published online in Diabetes Care ahead of print and presented at the 54th EASD Annual Congress in Berlin today.
INDIANAPOLIS , Oct. 4, 2018 /PRNewswire/ -- Results from a phase 2b clinical trial of Eli Lilly and Company's (NYSE: LLY) dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA, LY3298176) showed strong and ...
INDIANAPOLIS, Oct. 3, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) will announce its financial results for the third quarter of 2018 on Tuesday, November 6, 2018. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time.
URLi is Lilly's novel mealtime insulin formulation that was developed to help better control blood glucose levels after meals by more closely mirroring the way insulin works in people without diabetes. The two phase 3 studies, PRONTO-T1D and PRONTO-T2D, evaluated the safety and efficacy of URLi compared to Humalog in people with type 1 and type 2 diabetes, respectively.
INDIANAPOLIS , Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ™ (galcanezumab-gnlm) 120 mg injection ...
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, Chugai) and Eli Lilly and Company (NYSE: LLY, Lilly) today announced they have entered into a license agreement for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. Under the terms of the agreement, Lilly will receive worldwide development and commercialization rights to OWL833.
Elanco Animal Health Incorporated today announced the closing of its previously announced initial public offering (“IPO”) of 62.9 million shares of its common stock at a price to the public of $24.00 per share. In connection with the IPO, the underwriters exercised in full their option to purchase an additional 9.435 million shares of common stock at the price to the public less underwriting discounts, bringing the total IPO size to 72.335 million shares. As of the closing of the IPO, Eli Lilly and Company (“Lilly”) owns approximately 80.2% of Elanco, which it plans to divest through a tax-efficient transaction.
Elanco Animal Health Incorporated (ELAN) announced the underwriters of its initial public offering (IPO) have fully exercised their option to purchase an additional 9.435 million shares at the initial public offering price of $24.00 per share, less underwriting discounts, bringing the total IPO size to 72.335 million shares.
INDIANAPOLIS, Sept. 21, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality™ (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month. In June 2018, Lilly announced the intended brand name, Emgality™, was conditionally accepted by the U.S. Food and Drug Administration (FDA). Emgality is an investigational, once-monthly, self-administered injection under evaluation for the prevention of migraine, with no titration needed.
The shares are expected to begin trading on the New York Stock Exchange (NYSE) on September 20, 2018 under the ticker symbol “ELAN.” The offering is expected to close on September 24, 2018, subject to customary closing conditions. Elanco has granted the underwriters a 30-day option to purchase up to 9.435 million additional shares of common stock at the initial price to the public less underwriting discounts. Following the IPO, Lilly is expected to hold approximately 82.3% of Elanco (80.2% if the underwriters' option to purchase more shares is exercised in full).
INDIANAPOLIS, Sept. 13, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and the Indiana Bioscience Research Institute (IBRI), in collaboration with Indiana University School of Medicine, have created the Lilly Diabetes Center of Excellence (LDCE), which aims to establish a nexus of strategically aligned basic diabetes research operations in Indianapolis. The LDCE will recruit high-potential and established principal investigators (PIs) who aim to pursue cutting-edge research in diabetes, diabetic complications, and related metabolic disorders. The PIs will receive five-year sponsored appointments at the IBRI, subsidized by Lilly, and faculty appointments at IU School of Medicine.
Request for proposals issued for innovative strategies to improve patient outcomes for people with gastric and gastroesophageal junction cancer. Letters of intent due October 24. FORT WASHINGTON, Pa. and ...
- Fifteen abstracts supporting Taltz®, Olumiant® and mirikizumab reveal new findings for the treatment of psoriasis and atopic dermatitis - INDIANAPOLIS , Sept. 10, 2018 /PRNewswire/ -- Eli Lilly and Company ...
INDIANAPOLIS , Sept. 10, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the initiation of the IXORA-R head-to-head (H2H) clinical trial, designed to evaluate superiority between ...
INDIANAPOLIS , Sept. 6, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Thursday, October 4, 2018 to discuss the company's presentations at the 54 th annual meeting of ...
GREENFIELD, Ind., Sept. 6, 2018 /PRNewswire/ -- Elanco Animal Health Incorporated, a subsidiary of Eli Lilly and Company (LLY), today announced it has launched a roadshow for the initial public offering (IPO) of its common stock. Elanco is offering 62.9 million shares of its common stock in the IPO. The underwriters will also have a 30-day option to purchase up to 9.4 million additional shares of common stock at the IPO price, less underwriting discounts and commissions.